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Background: Combined pulmonary fibrosis and emphysema (CPFE) is a unique disorder that has
been previously described, and the distinct features of CPFE in comparison with chronic
obstructive pulmonary disease (COPD) have been reported. However, the yearly dynamics of
pulmonary function parameters in CPFE patients compared with those in COPD patients have
not yet been reported.
Methods: We retrospectively enrolled patients with CPFE and COPD who had undergone pul-
monary function tests more than five times during a follow-up period of more than five years.
The baseline clinical characteristics and the annual changes in pulmonary function during the
follow-up period in 16 stable CPFE patients were compared with those in 19 stable COPD pa-
tients. Annual changes in pulmonary function were estimated from linear regressions, with
assumptions for time-dependency and linearity. We analyzed the time-dependent fluctuations
in pulmonary function for the two disorders.
Results: Annual decreases in VC and FVC in the CPFE group were significantly higher than those
in the COPD group. Annual decrease in FEV1/FVC in the COPD group was significantly higher
than in the CPFE group. During the follow-up period, FEV1/FVC in the CPFE group appeared
to improve because of annual decrease in FVC. Annual decreases in DLco and DLco/VA in
the CPFE group were significantly higher than those in the COPD group.63 37 2393; fax: þ81 263 37 2370.
.ac.jp (K. Fujimoto).
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13.06.015
Annual changes in pulmonary function in CPFE 1987Conclusion: This is the first report showing the yearly dynamics of pulmonary function param-
eters in CPFE patients compared with those in COPD patients during a follow-up period of more
than five years. This study revealed that the physiologic consequences of CPFE including the
rate of progression of pulmonary function impairment were different from those of COPD.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
There is increasing clinical recognition of the coexistence of
emphysema and pulmonary fibrosis in individual patients,
resulting in a clinical syndrome known as combined pulmo-
nary fibrosis and emphysema (CPFE). CPFE is a unique dis-
order that has been described in several case series [1e5],
and the distinct features of CPFE in comparison with chronic
obstructive pulmonary disease (COPD) [3] and idiopathic
pulmonary fibrosis (IPF) [5e7] have been reported. CPFE was
characterized by subnormal spirometry (mild airflow limi-
tation and mild lung hyperinflation), severe impairment of
gas exchange and desaturation during exercise. The rela-
tively normal lung volumes in CPFE are usually attributed to
the counterbalancing effects of the restrictive defect of
pulmonary fibrosis and the propensity for hyperinflation seen
in emphysema [8]. The decrease in diffusing capacity of lung
for carbon monoxide (DLco) was more advanced in CPFE
patients than in COPD or IPF-alone patients. This phenome-
non was likely due to the additive effects of emphysema and
fibrosis in that both disorders reduce diffusing capacity.
Therefore, the physiologic consequences of CPFE were
different from those of COPD. However, the yearly dynamics
of pulmonary function parameters in CPFE patients
compared with those in COPD patients have not yet been
reported. Akagi et al. have investigated the yearly dynamics
of pulmonary function parameters in CPFE patients
comparedwith those in IPF-alonepatients, and reported that
the annual decrease in diffusion capacity was significantly
lower in CPFE patients than in IPF-alone patients [6]. We
retrospectively enrolled CPFE and COPD patients who had
undergone pulmonary function tests more than five times
during a follow-up period of more than five years, and
analyzed the time-dependent fluctuations in pulmonary
function in CPFE patients.Methods
Subjects
This study details the retrospective analysis of 16 stable
CPFE patients with concurrent emphysema and idiopathic
diffuse parenchymal lung disease with fibrosis based on
chest CT [9,10]. These outpatients were first seen at Shin-
shu University Hospital between April 2004 and December
2007, and were then followed up with over the next five or
more years. Exclusion criteria included the presence of
connective tissue disease and any other interstitial lung
disease, such as drug-induced interstitial lung disease,
pneumoconiosis, hypersensitivity pneumonitis, sarcoidosis,
pulmonary histiocytosis, lymphangioleiomyomatosis and
eosinophilic pneumonia. Nineteen stable COPD patients,who were first seen at Shinshu University Hospital between
April 2004 and December 2007, and were then followed up
with over the next five or more years, were recruited. The
diagnosis of COPD was based on the clinical history and
symptoms, including dyspnea while exercising and pulmo-
nary function characterized by irreversible airflow limita-
tion (FEV1/FVC < 70% after inhalation of a b2-agonist) in
accordance with the Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) guidelines [11]. The baseline
clinical characteristics and the annual change in pulmonary
function during the follow-up period in CPFE patients were
compared with those in stable COPD patients. Stable pa-
tients were defined as those who had not suffered from
respiratory tract infections or an exacerbation of COPD or
pulmonary fibrosis during the preceding three months.
A total of 20 consecutive CPFE patients were seen at our
hospital and followed up for five or more years. However,
one patient who underwent a surgical lung biopsy and three
patients who underwent lobectomy as a result of lung
cancer were excluded from this study, since the procedure
may influence pulmonary function. In total, 16 patients
were included in the CPFE group. On the other hand, a total
of 40 consecutive COPD patients were seen at our hospital
and followed up for five or more years. However, nine COPD
patients with “absence of emphysema, with little emphy-
sema phenotype” [12,13] were excluded from this study,
because our imaging criteria of COPD and CPFE included the
percentage ratio of low attenuation area (%LAA) 25% on
chest HRCT [3]. Six COPD patients who had any history of
asthma or asthmatic symptoms, three patients who un-
derwent lobectomy as a result of lung cancer and three
patients who underwent lung volume reduction surgery for
COPD were excluded from this study. In total, 19 patients
were included in the COPD group. This study was approved
by the institutional Human Ethics Committee.
Evaluation of emphysema and diffuse parenchymal
lung disease with significant pulmonary fibrosis on
chest HRCT
Emphysema and diffuse parenchymal lung disease with sig-
nificant pulmonary fibrosis were evaluated using chest HRCT
as described previously [12,13]. Briefly, emphysema was
scored visually in bilateral upper, middle and lower lung
fields according to the methods of Goddard et al. [9]. The
score in each of the 6 dimensions was calculated according
to %LAA in each lung field as follows: score 0, %LAA < 5%;
score 1, 5%  %LAA < 25%; score 2, 25%  %LAA < 50%; score
3, 50%  %LAA < 75%; score 4, 75%  %LAA. The severity of
emphysema was graded in accordance with the sum of the
scores at the 6 dimensions as follows: Grade 0, total
score Z 0; Grade 1, total scores Z 1e6; Grade 2, total
scores Z 7e12; Grade 3, total scores Z 13e18; Grade 4,
Table 2 Clinical characteristics during the follow-up
period in the CPFE and COPD groups.
CPFE
(n Z 16)
COPD
(n Z 19)
Follow-up period,
years
6.47  0.38 6.92  0.30
Smoking status*
Continuous smoker,
n(%)
1(6.3) 1(5.3)
Intermittent smoker,
n(%)
0(0) 0(0)
Former smoker, n(%) 15(93.8) 18(94.7)
Medication for COPD**
Any medication,
n(%)
7(43.8)yy 19(100)
LAMA, n(%) 4(25.0)yy 15(78.9)
LABA, n(%) 3(18.8)yy 13(68.4)
ICS, n(%) 1(6.3) 5(26.3)
Theophyllline, n(%) 3(18.8)y 11(57.9)
Values are the number (%) or the means  SEM. yp < 0.05 and
yyp < 0.01 vs. COPD; Definition of abbreviations: CPFE, com-
bined pulmonary fibrosis and emphysema; COPD, chronic
obstructive pulmonary disease; LAMA, long-acting muscarinic
antagonist; LABA, long-acting b2-agonist; ICS, inhaled cortico-
1988 Y. Kitaguchi et al.total scoresZ 19e24. The presence of diffuse parenchymal
lung disease with significant pulmonary fibrosis on HRCT,
defined as thick-walled bulla, honeycombing, reticular
opacities, ground-glass opacities, consolidation, traction
bronchiectasis, peribronchovascular interstitial thickening
and architectural distortion, were evaluated as described
previously [3]. CT images were analyzed independently by
two pulmonologists (Y.K. and K.F.) with no knowledge of the
patients’ clinical information. CPFE patients were charac-
terized by the coexistence of significant emphysema (Grade
2 or more, %LAA  25%) and diffuse parenchymal lung dis-
ease with significant pulmonary fibrosis. COPD patients were
characterized by the presence of significant emphysema
(Grade 2 or more, %LAA  25%) without any significant pul-
monary fibrosis.
Pulmonary function tests
Both spirometry and the measurement of DLco and DLco
corrected for alveolar volume (DLco/VA) were performed
using a pulmonary function testing system (Chestac-55V;
Chest Co. Ltd.). The functional residual capacity (FRC) was
measured using a Body Box (Medgraphic, Ann Harbor, MI),
after which the subjects immediately inspired to total lung
capacity (TLC) and maximally expired to residual volumeTable 1 Baseline clinical characteristics and pulmonary
function in the CPFE and COPD groups.
CPFE
(n Z 16)
COPD
(n Z 19)
Gender
(Male/Female)
16/0 19/2
Age at first visit,
yr
66.8  1.8 67.7  1.1
Body Mass Index,
kg/m2
22.9  0.7 21.5  0.7
Smoking index,
pack-years
67.9  5.3 57.6  5.5
VC, % predicted 97.0  4.6 88.5  4.8
FVC, % predicted 98.1  4.5 85.6  4.8
FEV1, L 2.37  0.16yy 1.48  0.14
FEV1, % predicted 81.4  6.0yy 54.2  4.6
FEV1/FVC, % 67.6  3.5yy 49.6  2.5
FRC, % predicted 103.7  6.1yy 142.1  9.6
RV, % predicted 141.2  12.4yy 221.2  12.9
TLC, % predicted 112.2  6.0y 133.0  5.0
RV/TLC, % 42.2  2.9yy 53.8  2.3
DLco, % predicted 56.7  6.2 64.9  4.9
DLco/VA, %
predicted
66.9  5.8 70.9  5.3
Values are the number (%) or the means  SEM. yp < 0.05 and
yyp < 0.01 vs. COPD; Definition of abbreviations: CPFE, com-
bined pulmonary fibrosis and emphysema; COPD, chronic
obstructive pulmonary disease; VC, vital capacity; FVC, forced
vital capacity; FEV1, forced expiratory volume in one second;
FRC, functional residual capacity; RV, residual volume; TLC,
total lung capacity; DLco, diffusing capacity of lung for carbon
monoxide; DLco/VA, diffusing capacity of lung for carbon
monoxide corrected for alveolar volume.
steroid; * Subjects were described as continuous, intermittent,
or former smokers, depending of the smoking status during the
follow-up period.; ** Numbers denote the number of subjects
with more than 50% of usage during the follow-up period.
Table 3 Annual changes in pulmonary function in the
CPFE and COPD groups.
CPFE
(n Z 16)
COPD
(n Z 19)
VC, ml/year 113.5  41.3y 11.0  13.9
FVC, ml/year 88.2  28.5y 15.6  16.6
FEV1, ml/year 57.7  26.7 34.8  8.8
FEV1, % predicted/
year
0.98  0.91 0.76  0.34
FEV1/FVC, %/year 0.31  0.45y 0.94  0.24
FRC, ml/year 20.9  29.2 57.3  20.8
RV, ml/year 9.5  36.1 41.0  22.8
TLC, ml/year 93.7  37.4 61.3  16.4
DLco, ml/min/
mmHg/year
1.15  0.22yy 0.51  0.10
DLco/VA, ml/min/
mmHg/l/year
0.22  0.05yy 0.06  0.03
Values are the means  SEM. yp < 0.05 and yyp < 0.01 vs. COPD;
Definition of abbreviations: CPFE, combined pulmonary fibrosis
and emphysema; COPD, chronic obstructive pulmonary disease;
VC, vital capacity; FVC, forced vital capacity; FEV1, forced
expiratory volume in one second; FRC, functional residual ca-
pacity; RV, residual volume; TLC, total lung capacity; DLco,
diffusing capacity of lung for carbon monoxide; DLco/VA,
diffusing capacity of lung for carbon monoxide corrected for
alveolar volume.
Figure 1 (a & b) Changes in vital capacity (VC) observed during the follow-up period in all CPFE and COPD patients; (c) change
per year in VC in the CPFE and COPD groups; annual decrease in VC in the CPFE group was significantly higher than in the COPD
group (p < 0.05).
Annual changes in pulmonary function in CPFE 1989(RV), thus allowing for calculation of lung volumes and of
RV/TLC. The pulmonary function tests were performed by
two special technicians according to the American Thoracic
Society criteria. Two or three tests were repeated to
guarantee repeatability.
Pulmonary function tests were repeated during the
course of the study. Baseline pulmonary function was
estimated from the first tests conducted at our hospital. To
estimate the annual change in pulmonary function, we used
data from patients who had undergone pulmonary function
tests more than five times during a follow-up period of
more than five years. Annual changes in pulmonary function
were estimated from linear regressions, with assumptions
for time-dependency and linearity.
Data analysis
The values shown in the text, figures and tables represent
means  standard error of the mean (SEM). The baseline
values and changes per year in the parameters of pul-
monary function in the CPFE and COPD groups were
compared using unpaired t-test. Categorical variables
such as gender, age, smoking status, and medication for
COPD were evaluated using Fisher’s exact test. AllFigure 2 (a & b) Changes in forced vital capacity (FVC) observed
change per year in FVC in the CPFE and COPD groups; annual decrea
COPD group (p < 0.05).statistical analyses were performed using a Windows-
compatible software (Stat Flex version 5.0; Artech,
Osaka, Japan). A value of P < 0.05 was considered to
be significant for the results of all statistical analyses.
Results
Baseline clinical characteristics and pulmonary function of
the CPFE and COPD groups are shown in Table 1. There
were no significant differences in percent predicted vital
capacity (VC) and percent predicted forced vital capacity
(FVC) between the COPD and CPFE groups. Forced expi-
ratory volume in one second (FEV1), percent predicted
FEV1 and FEV1/FVC were significantly higher in the CPFE
group. Percent predicted FRC, percent predicted RV,
percent predicted TLC and RV/TLC were significantly
lower in the CPFE group. There were no significant dif-
ferences in percent predicted DLco and percent predicted
DLco/VA, although percent predicted DLco tended to be
lower in the CPFE group.
There was no significant difference in the average
follow-up period after the first visit between the two
groups (Table 2). One patient in each group was a current
smoker, all other patients were former smokers. Theduring the follow-up period in all CPFE and COPD patients; (c)
se in FVC in the CPFE group was significantly higher than in the
Figure 3 (a & b) Changes in forced expiratory volume in one second/forced vital capacity (FEV1/FVC) observed during the follow-
up period in all CPFE and COPD patients; (c) change per year in FEV1/FVC in the CPFE and COPD groups; annual decrease in FEV1/
FVC in the COPD group was significantly higher than that in the CPFE group (p < 0.05).
1990 Y. Kitaguchi et al.number of patients who had received any medication for
COPD was significant smaller in the CPFE group. None of the
patients from either group had received oral steroids or
immunosuppressants treatment.
Annual changes in pulmonary function are shown in Table
3. Changes in VC, FVC, FEV1/FVC, DLco and DLco/VA
observed during the follow-up period in all patients are
presented in Figs. 1e5. Annual decreases in VC and FVC in
the CPFE group were significantly higher than those in the
COPD group (Table 3, Figs. 1 and 2). There were no signifi-
cant differences in annual decrease in FEV1 and percent
predicted FEV1 between the two groups. Annual decrease in
FEV1/FVC in the COPD group was significantly higher than
that in the CPFE group (Table 3, Fig. 3). FEV1/FVC in the
CPFE group appeared to improve during the follow-up period
because of annual decrease in FVC. Annual decreases in
DLco and DLco/VA in the CPFE group were significantly
higher than those in the COPD group (Table 3, Figs. 4 and 5).Discussion
This study is the first to compare the yearly dynamics of
pulmonary function parameters in CPFE patients with those
in COPD patients. This study revealed that airflow limita-
tion represented as FEV1/FVC appeared to improve duringFigure 4 (a & b) Changes in diffusing capacity of lung for carbo
CPFE and COPD patients; (c) change per year in DLco in the CPFE an
significantly higher than those in the COPD group (p < 0.01).the follow-up period of more than five years in CPFE pa-
tients because of the annual decrease in FVC. The annual
decreases in DLco and DLco/VA were significantly higher in
the CPFE group provably due to the additive effects of
emphysema and fibrosis, in that both reduce diffusing ca-
pacity. These findings suggest that the physiologic conse-
quences of CPFE including the rate of progression of
pulmonary function impairment were different from those
of COPD. There was no significant difference between the
two groups in the annual change in FEV1, which is the
parameter most commonly used to assess the course of
COPD [14] and to predict future changes in pulmonary
function and survival in COPD [15].
Akagi et al. reported that ventilatory and gas-exchange
deterioration during the course of IPF became mild when
emphysema was coexistent [6]. This study has demon-
strated that the annual decreases in VC, FVC, DLco and
DLco/VA were more advanced in CPFE patients than in
COPD patients. However, there is a potential problem with
the differences in imaging criteria between these two
studies. We based a clinical diagnosis of CPFE on the im-
aging criteria for CPFE as described by Cottin et al. [1],
which included idiopathic interstitial pneumonias other
than IPF. CPFE patients in this study also had the presence
of significant emphysema (Grade 2 or more, %LAA  25%).
Therefore, one possibility is that CPFE patients in this studyn monoxide (DLco) observed during the follow-up period in all
d COPD groups; annual decrease in DLco in the CPFE group were
Figure 5 (a & b) Changes in diffusing capacity of lung for carbon monoxide corrected for alveolar volume (DLco/VA) observed
during the follow-up period in all CPFE and COPD patients; (c) change per year in DLco/VA in the CPFE and COPD groups; annual
decrease in DLco/VA in the CPFE group were significantly higher than those in the COPD group (p < 0.01).
Annual changes in pulmonary function in CPFE 1991may have been in a different phase and/or a different
disease state compared with those in the previous report
described by Akagi et al. [6]. Standard clinical diagnostic
criteria for CPFE needed to be established, particularly for
imaging, even though the imaging findings and pathology in
CPFE patients are heterogeneous [2].
Previous studies have investigated the predictors of
mortality for CPFE in pulmonary function parameters.
Schmidt et al. reported that longitudinal decline in FEV1
over 12 months was more predictive of mortality in CPFE
patients than the other pulmonary function parameters
[16]. Kishaba et al. reported that a value of more than 1.2
for the ratio of percent predicted FEV1 to percent predicted
FVC was an independent predictor of mortality in CPFE
patients [17]. Mejı´a et al. reported that the Cox regression
model showed that a FVC less than 50% predicted was one
of the most important variables associated with mortality in
patients with IPF and emphysema [18]. In contrast, longi-
tudinal changes in FVC and DLco have been shown to have
prognostic value in IPF [19e22]. Therefore, it may be
helpful to measure the longitudinal changes in FVC and
DLco as a prognostic predictor in CPFE as well as IPF. In
addition, pulmonary function parameters with large longi-
tudinal changes such as VC, FVC, DLco and DLco/VA may be
shown to have prognostic values in CPFE. Further studies to
elucidate the roles of ventilation and gas-exchange im-
pairments as prognostic factors are needed in CPFE.
There were several limitations in this study. First, this
was a single-centre, uncontrolled design retrospective
study. Additional prospective studies with large sample
sizes are warranted to confirm our results. Second, the
assessment of emphysema was done by a visual scoring
method, rather than by using a software-based quantifica-
tion of emphysema. However, the reproducibility of visual
scoring had been demonstrated in our previous report [13].
Third, we did not measure the exact areas of fibrosis.
Forth, the differences in pharmacotherapy between CPFE
and COPD groups may influence the results. The number of
patients who had received any medication for COPD was
significant larger in the COPD groups. For this reason, the
values of the pulmonary function parameters may have
varied widely during the follow-up period especially in the
COPD patients. Fifth, we could not evaluate the detailed
pathology of our CPFE patients, because patients who un-
derwent a surgical lung biopsy were excluded from thestudy, since the procedure influences pulmonary functions.
Sixth, a linear regression analysis was employed to analyze
longitudinal changes in the pulmonary function, based on
previous reports describing longitudinal changes in pulmo-
nary function [6,23,24]. Therefore, a mixed-effects analysis
was not employed in this study. However a linear regression
analysis may not be a reasonable assumption in some cases
according to the figures, which may also have affected the
results. In addition, the unpaired t-test may not appro-
priate for the statistical analysis of annual changes in the
pulmonary function due to the small sample size. There-
fore, further studies with larger sample sizes are needed to
confirm our results. Seventh, one potential problem with
this study is generalizability. Patients who underwent a
lobectomy as a result of lung cancer were excluded from
this study, since the procedure may influence pulmonary
function. Therefore, a selection bias may exist, because
the prevalence of lung cancer may be high in CPFE patients
[3,25]. This study details the retrospective analysis of sta-
ble CPFE and COPD patients who had been followed up for
more than five years. Therefore, patients with an advanced
disease who died during the course of CPFE were not
included in this study. In fact, there was no significant
difference in DLco between the COPD and CPFE groups in
this study, even though several previous reports have
documented a significant decrease in DLco in CPFE patients
[1e5]. This discrepancy between previous findings and
those from this study may suggest that the proportion of
patients with a mild disease was relative large in this study.
In conclusion, this is the first report showing the yearly
dynamics of pulmonary function parameters in CPFE pa-
tients compared with those in COPD patients during a
follow-up period of more than five years. The annual de-
creases in DLco and DLco/VA were significantly higher in
CPFE patients. Airflow limitation represented as FEV1/FVC
appeared to improve during the course of CPFE because of
the annual decrease in FVC. This study revealed that the
physiologic consequences of CPFE including the rate of
progression of pulmonary function impairment were
different from those of COPD.Disclosure
The authors report no conflicts of interest in this work.
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